Knowledge Tree
olaparib
Facts (4)
Sources
Perspectives on cancer therapy—synthetic lethal precision medicine ... nature.com Apr 16, 2025 2 facts
claimThe ATM inhibitor AZD0156 demonstrates the ability to potentiate irradiation and olaparib responses in preclinical models.
referenceA 2020 study in Molecular Cancer Therapeutics by Riches et al. details the pharmacology of the ATM inhibitor AZD0156, noting its ability to potentiate irradiation and olaparib responses in preclinical models.
The Biological Basis for Women's Health Through the Lens of ... - NCBI ncbi.nlm.nih.gov 1 fact
measurementThe FDA approved olaparib, the first PARP inhibitor, in 2014 for patients with advanced ovarian cancers harboring BRCA mutations.
10 Breakthrough Research and Clinical Trials Shaping the ... honcology.com Dec 29, 2025 1 fact
claimHirschfeld Oncology utilizes molecular profiling to direct the use of targeted therapies, such as PARP inhibitors like Olaparib, for patients with specific genetic subgroups.